Funded Biomarker Testing
69 items
Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.
Funded Biomarker Disease Site: Endometrium
Biomarker: P53, PR, ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma.
Funded Biomarker Disease Site: Endometrium
Biomarker: POLE, CTNNB1, KRAS, PIK3CA, PTEN, TP53
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma.
Funded Biomarker Disease Site: Head and Neck
Biomarker: PD-L1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.
Funded Biomarker Disease Site: Bladder/ Urothelial
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with uveal melanoma.
Funded Biomarker Disease Site: Ocular
Biomarker: GNAQ, GNA11
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Reflex testing should be performed on tumours from newly diagnosed adult patients with astrocytic and oligodendroglial tumours, including glioblastomas (all diffuse high-grade gliomas Stage III and IV).
Funded Biomarker Disease Site: Central Nervous System (CNS)
Biomarker: IDH R132H, P53, ATRX
Testing Method:Immunohistochemistry (IHC)
Testing Site: London Health Sciences Centre, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network
Reflex testing to confirm or exclude small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Funded Biomarker Disease Site: Ovary
Biomarker: SMARCA4
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Trillium Health Partners, University Health Network, William Osler Health System
Reflex tumour testing for all patients diagnosed with high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Funded Biomarker Disease Site: Ovary
Biomarker: BRCA1, BRCA2
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System
Repeat FLT3 testing of adult patients with relapsed or refractory acute myeloid leukemia being considered for therapy with Gilteritinib.
Funded Biomarker Disease Site: Hematology
Biomarker: FLT3
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, St. Joseph's Healthcare Hamilton, The Ottawa Hospital, University Health Network
Review of tumour by a subspecialist Pathologist for classification
Funded Biomarker Disease Site: Soft Tissue
Biomarker:
Testing Method:
Testing Site: Hamilton Health Sciences, Mount Sinai Hospital, The Ottawa Hospital
Serous (high grade/advanced) endometrial carcinoma where HER2 directed therapy is being considered.
Funded Biomarker Disease Site: Endometrium
Biomarker: HER2
Testing Method:In Situ Hybridization (ISH)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Testing on advanced/metastatic breast cancer where directed therapy is being considered.
Funded Biomarker Disease Site: Breast
Biomarker: ESR1, PIK3CA
Testing Method:Panel
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System